Insider Transactions of CRISPR Therapeutics AG

Raju, Chief Financial Officer of CRISPR Therapeutics AG, reported several transactions on March 14 and 16, 2026. On March 14, 10,000 and 6,875 Restricted Stock Units (RSUs) were acquired, which correspond to Common Shares. Also on March 14, 10,000 and 6,875 Common Shares were acquired. On March 16, 5,848 and 4,021 Common Shares were disposed of at a price of $48.26 per share to cover tax withholding obligations related to RSU vesting. An additional 750 Common Shares were disposed of as a gift on March 16. Some of these transactions were subject to a lock-up agreement related to the offering of convertible senior notes due 2031. The RSUs were granted in 2023 and 2025, with vesting schedules extending to 2027 and 2029, respectively. Footnote F3 clarifies that the sales for tax withholding are mandated by company policy and do not represent discretionary trades.